Wide variation in reports suggests that anywhere between 9.1 and 72.2% of BTCs are PD-L1 positive and like other cancers, it appears that PD-L1 expression in BTC is an imperfect biomarker to predict response to immunotherapy [33,34,35]. Here, CD274 is linked to cancer.